The arrival of the Retatrutide vial signifies a potential advance in the approach to weight regulation. This innovative drug combines dual mechanisms – activation of the GLP-1 target and inhibition of the DPP-4 enzyme – providing a unique strategy for tackling obesity . Early patient results suggest promising results in promoting meaningful wei